Organization Profile

You just read:

Aeterna Zentaris: Final Phase 2 Data Demonstrate Perifosine and Sorafenib Combination Therapy Well Tolerated by Heavily Pretreated Lymphoma Patients

News provided by

AETERNA ZENTARIS INC.

Dec 11, 2012, 07:30 ET